La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Inter Pharma Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Inter Pharma ha un patrimonio netto totale di THB2.1B e un debito totale di THB247.9M, che porta il suo rapporto debito/patrimonio netto a 11.7%. Le sue attività totali e le sue passività totali sono rispettivamente THB2.9B e THB763.8M. L'EBIT di Inter Pharma è THB56.2M rendendo il suo rapporto di copertura degli interessi 2.5. Ha liquidità e investimenti a breve termine pari a THB310.1M.

Informazioni chiave

11.7%

Rapporto debito/patrimonio netto

฿247.90m

Debito

Indice di copertura degli interessi	2.6x
Contanti	฿310.92m
Patrimonio netto	฿2.12b
Totale passività	฿763.83m
Totale attività	฿2.88b

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( THB1.1B ) di IP superano le sue passività a breve termine ( THB429.7M ).

Passività a lungo termine: Le attività a breve termine di IP ( THB1.1B ) superano le sue passività a lungo termine ( THB334.1M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: IP ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di IP si è ridotto da 14.4% a 11.7% negli ultimi 5 anni.

Copertura del debito: Il debito di IP è ben coperto dal flusso di cassa operativo ( 61.8% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di IP non sono ben coperti dall'EBIT ( 2.5 x copertura).

Inter Pharma Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Second quarter 2024 earnings released: EPS: ฿0.006 (vs ฿0.019 in 2Q 2023)

Investor sentiment deteriorates as stock falls 26%

New minor risk - Share price stability

First quarter 2024 earnings released: EPS: ฿0.042 (vs ฿0.066 in 1Q 2023)

Investor sentiment deteriorates as stock falls 40%

Inter Pharma Public Company Limited Approves Dividend for the Year 2023, Payable on May 24, 2024

Now 20% overvalued

Dividend reduced to ฿0.035

Full year 2023 earnings: EPS and revenues miss analyst expectations

Inter Pharma Public Company Limited Proposes Dividend for the Year 2023, Payable on May 24, 2024

Less than half of directors are independent

Third quarter 2023 earnings released: EPS: ฿0.037 (vs ฿0.09 in 3Q 2022)

New minor risk - Market cap size

Consensus EPS estimates fall by 32%

Second quarter 2023 earnings released: EPS: ฿0.03 (vs ฿0.10 in 2Q 2022)

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 16%

Price target decreased by 9.7% to ฿18.10

Investor sentiment deteriorates as stock falls 25%

Inter Pharma Public Company Limited Announces CFO Changes

Investor sentiment deteriorates as stock falls 22%

First quarter 2023 earnings released: EPS: ฿0.11 (vs ฿0.10 in 1Q 2022)

Upcoming dividend of ฿0.18 per share at 1.6% yield

Price target decreased by 13% to ฿18.65

Inter Pharma Public Company Limited Announces Resignation of Terdkiat Prommool as Director

Consensus forecasts updated

Less than half of directors are independent

Second quarter 2022 earnings released: EPS: ฿0.10 (vs ฿0.086 in 2Q 2021)

Inter Pharma Public Company Limited announced that it has received THB 1.04314 billion in funding from Innobic LL Holding Company Limited

Inter Pharma Public Company Limited Approves Election of Directors

Inter Pharma Public Company Limited Announces Chief Financial Officer Changes

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased to ฿26.00

High number of new and inexperienced directors

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Inter Pharma Public Company Limited Proposes Omission of Dividend Payment for 2021

Consensus forecasts updated

Consensus forecasts updated

Third quarter 2021 earnings released: EPS ฿0.088 (vs ฿0.064 in 3Q 2020)

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS ฿0.086 (vs ฿0.059 in 2Q 2020)

First quarter 2021 earnings released: EPS ฿0.091 (vs ฿0.048 in 1Q 2020)

Inter Pharma Public Company Limited Approves Cash Dividends for 2020, Payable on May 18, 2020

Revenue and earnings miss expectations

Full year 2020 earnings released: EPS ฿0.26 (vs ฿0.28 in FY 2019)

Inter Pharma Public Company Limited, Annual General Meeting, Apr 26, 2021

Inter Pharma Public Company Limited (SET:IP) entered into an agreement to acquire Certain Assets of Teva Pharma (Thailand) Co., Ltd. from Teva Pharma (Thailand) Co., Ltd. for THB 160 million.

Investor sentiment improved over the past week

Inter Pharma Public Company Replaces Amornsakdi Ketcharoon with Kamtorn Sila-On as an Independent Director, Audit Committee, Chairman of the Nomination and Remuneration Committee and Corporate Governance and Sustainable Development Committee, Effective February 8, 2021

New 90-day high: ฿19.70

Independent Director has left the company

Inter Pharma Public Company Limited Notifies the Resignation of Mr. Amornsakdi Ketcharoon from Independent Director, Audit Committee, Chairman of the Nomination and Remuneration Committee and Corporate Governance and Sustainable Development Committee ,Effective from January 31, 2021

Investor sentiment improved over the past week

New 90-day high: ฿14.00

New 90-day high: ฿13.60

Third quarter 2020 earnings released: EPS ฿0.09

Interpharma Public Company Limited Announces Director Changes

New 90-day high - ฿13.40

Earnings released

New 90-day high - ฿11.70

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane